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The use of antidepressants in children and adolescents remains controversial. We exam-
ined trends over time and variation in antidepressant prescribing in children and young peo-
ple in England and whether the drugs prescribed reflected UK licensing and guidelines.
Methods and findings
QResearch is a primary care database containing anonymised healthcare records of over
32 million patients from more than 1,500 general practices across the UK. All eligible chil-
dren and young people aged 5–17 years in 1998–2017 from QResearch were included. Inci-
dence and prevalence rates of antidepressant prescriptions in each year were calculated
overall, for 4 antidepressant classes (selective serotonin reuptake inhibitors [SSRIs], tricy-
clic and related antidepressants [TCAs], serotonin and norepinephrine reuptake inhibitors
[SNRIs], and other antidepressants), and for individual drugs. Adjusted trends over time and
differences by social deprivation, region, and ethnicity were examined using Poisson regres-
sion, taking clustering within general practitioner (GP) practices into account using multilevel
modelling. Of the 4.3 million children and young people in the cohort, 49,434 (1.1%) were
prescribed antidepressants for the first time during 20 million years of follow-up. Males
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made up 52.0% of the cohorts, but only 34.1% of those who were first prescribed an antide-
pressant in the study period. The largest proportion of the cohort was from London (24.4%),
and whilst ethnicity information was missing for 39.5% of the cohort, of those with known
ethnicity, 75.3% were White. Overall, SSRIs (62.6%) were the most commonly prescribed
first antidepressant, followed by TCAs (35.7%). Incident antidepressant prescribing
decreased in 5- to 11-year-olds from a peak of 0.9 in females and 1.6 in males in 1999 to
less than 0.2 per 1,000 for both sexes in 2017, but incidence rates more than doubled in 12-
to 17-year-olds between 2005 and 2017 to 9.7 (females) and 4.2 (males) per 1,000 person-
years. The lowest prescription incidence rates were in London, and the highest were in the
South East of England (excluding London) for all sex and age groups. Those living in more
deprived areas were more likely to be prescribed antidepressants after adjusting for region.
The strongest trend was seen in 12- to 17-year-old females (adjusted incidence rate ratio
[aIRR] 1.12, 95% confidence interval [95% CI] 1.11–1.13, p < 0.001, per deprivation quintile
increase). Prescribing rates were highest in White and lowest in Black adolescents (aIRR
0.32, 95% CI 0.29–0.36, p < 0.001 [females]; aIRR 0.32, 95% CI 0.27–0.38, p < 0.001
[males]). The 5 most commonly prescribed antidepressants were either licensed in the UK
for use in children and young people (CYP) or included in national guidelines. Limitations of
the study are that, because we did not have access to secondary care prescribing informa-
tion, we may be underestimating the prevalence and misidentifying the first antidepressant
prescription. We could not assess whether antidepressants were dispensed or taken.
Conclusions
Our analysis provides evidence of a continuing rise of antidepressant prescribing in adoles-
cents aged 12–17 years since 2005, driven by SSRI prescriptions, but a decrease in chil-
dren aged 5–11 years. The variation in prescribing by deprivation, region, and ethnicity
could represent inequities. Future research should examine whether prescribing trends and
variation are due to true differences in need and risk factors, access to diagnosis or treat-
ment, prescribing behaviour, or young people’s help-seeking behaviour.
Author summary
Why was this study done?
• A substantial increase has been noted in the UK and other countries in the prescription
of antidepressant medicines for young people, despite their benefits and safety remain-
ing matters for debate.
• Several antidepressants are included in UK guidelines for children and young people,
though not all are currently licensed for use in under 18s in the UK.
• It remains unclear whether there is variation in prescribing across different groups and
if the choice of medicines used in real-world practice adheres to evidence-based clinical
guidelines.
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What did the researchers do and find?
• We examined the incidence and prevalence of antidepressant prescribing in a cohort of
over 4.3 million 5- to 17-year-olds in England from a large primary care database
between 1998 and 2017.
• Antidepressant prescribing decreased in 5- to 11-year-olds between 1999 and 2017 but
more than doubled in 12- to 17-year-olds between 2005 and 2017.
• There was variation in prescribing by deprivation, region, and ethnicity, even after tak-
ing other factors into account.
What do these findings mean?
• The variation in prescribing by deprivation, region, and ethnicity found could represent
inequities in care and service provision.
• Future research should examine whether prescribing trends and variation are due to dif-
ferences in need or barriers in accessing diagnosis or treatment.
Introduction
Depressive disorders were the third largest cause of adolescent disability-adjusted life years
lost globally in 2015 [1]. Compared with adults, children and young people (CYP) with major
depressive disorder are still underdiagnosed and undertreated [2,3]. Consequences of depres-
sive episodes in young people include serious impairments in social functioning and school
performance, as well as suicidal ideation and attempts [4]. Psychological treatments are still
considered the first-line treatment in many clinical guidelines, including the UK National
Institute for Health and Care Excellence (NICE) guidelines for depression in CYP [5]. How-
ever, 22.7% of CYP with emotional disorders reported waiting more than 6 months to see a
mental health specialist in England in 2017 [6], and antidepressants are widely used in the
treatment of depression in children and adolescents.
The efficacy and safety of antidepressant medicines for major depression in CYP remains
controversial [7]. Fluoxetine is the only antidepressant licensed for use in CYP as a first-line
treatment for major depression in the UK [8] and the US [9]. In the UK, other antidepressants
are licensed for obsessive-compulsive disorder (fluvoxamine and sertraline) and nocturnal
enuresis (imipramine), and these drugs are recommended as the first antidepressants to use by
the relevant NICE guidelines [10,11]. Amitriptyline has neuropathic pain listed as an unli-
censed indication in the British National Formulary for Children [8] and is suggested as a pro-
phylactic treatment for migraines in NICE guidelines on headaches in over-12s [12]. Tricyclic
antidepressants, in particular imipramine, have historically been used as a second or third line
drug in the management of attention-deficit hyperactivity disorder (ADHD) in children
despite being unlicensed for this indication [8]. Therefore, examining the trends in antidepres-
sants prescribed to CYP may indicate changes in relation to the indications these drugs are
licensed for, as well as whether NICE guidelines and evidence-based practice are being fol-
lowed. According to NICE guidelines, in the UK, prescribing antidepressants to CYP should
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within clinical computer systems to help improve
patient care.
Abbreviations: ADHD, attention-deficit hyperactive
disorder; aIRR, adjusted IRR; CAMHS, Child and
Adolescent Mental Health Services; CI, confidence
interval; CYP, children and young people; EMIS,
Egton Medical Information Systems; GP, general
practitioner; HES, hospital episode statistics; IRR,
incidence rate ratio; MAOI, monoamine oxidase
inhibitor; NHS, National Health Service; NICE,
National Institute for Health and Care Excellence;
NIHR, National Institute for Health Research; SNRI,
serotonin and norepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor; TCA,
tricyclic and related antidepressant.
only be done after assessment and diagnosis by a child and adolescent psychiatrist [5,10] or
other specialist with expertise in child and adolescent mental health [11]. Referral to specialists
in secondary care would usually be made, when appropriate, after visiting a general practi-
tioner (GP) in primary care [13]. Work examining indications recorded in primary care
around the time of the first antidepressant prescription and which secondary care specialists
were seen has been done separately [14].
Antidepressant prescriptions for young people were increasing until a drop in 2002, and
then began significantly increasing again from 2005 both in the UK [15–19] and other coun-
tries [20–23]. Increased prescribing of antidepressants could indicate a greater awareness and
recognition of mental health and related issues and a willingness to seek help in the form of
being diagnosed and/or treated. There is some evidence that in people of all ages, antidepres-
sant prescribing varies by region [24] and between different ethnic groups in England [25,26].
Previous studies showing that CYP living in more deprived areas are more likely to receive
antidepressant prescriptions have not taken region or ethnicity into account [15,16]. There is
generally a lack of evidence about variation in antidepressant prescribing in CYP, particularly
taking other possibly confounding factors into account. Differences in prescribing by depriva-
tion, geographical location, and ethnicity could indicate differences in the distribution of risk
factors for mental health disorders and/or differences in access to psychological therapies,
which could both affect the likelihood of antidepressant prescribing.
It remains unclear, based on previous studies, whether the reported rise in antidepressant
prescribing in CYP that began in 2005 is continuing and whether there is variation in prescrib-
ing across different groups. Our study aimed to examine changes over time and the variation
in the use of antidepressant medicines in CYP aged between 5 and 17 years old between 1998
and 2017 in England. Our objectives were to 1) describe differences in antidepressant prescrip-
tions for CYP over time by age, sex, deprivation, region, and ethnicity; 2) estimate variation in
prescribing between these groups adjusting for the other factors; and 3) assess to what extent
NICE guidelines for CYP are being adhered to.
Methods
The full protocol for the study has previously been published [27]. Any analyses that were not
prespecified in the protocol are described as sensitivity or post hoc analyses below. This study
is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guideline (see S1 STROBE Checklist).
Data sources
The cohort was extracted from a large primary care database (QResearch, version 43) linked to
hospital episode statistics (HES) admitted patient care and outpatient data. At the time of the
study, the QResearch database included health records of over 32 million patients from more
than 1,500 general practices across the UK that record data using the Egton Medical Informa-
tion Systems (EMIS) medical records computer system.
Study participants
The study’s open cohort was defined as all people registered on the QResearch database in
England who were aged between 5 and 17 years between 1 January 1998 and 31 December
2017. Each person’s study entry date was defined as the latest date of the following: 12 months
after their registration with a study practice, 12 months after the installation date of their prac-
tice’s EMIS computer system, 1 January of the year they turned 5 years old, or 1 January 1998.
People were then followed up until the earliest date of them leaving the practice, dying, 1
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January of the year they turned 18 years old, or the end of the follow-up period (31 December
2017).
Outcomes
We extracted information on prescriptions for any antidepressant for each person in the
cohort. In some cases, we had prescribing information from before a patient registered with a
practice because of electronic transferring of prescription data or before the practice installed
EMIS. In this way, we could identify prescriptions that took place before the study period. We
examined all antidepressants combined and 4 different drug classes: selective serotonin reup-
take inhibitors (SSRIs), tricyclic and related antidepressants (TCAs), serotonin and norepi-
nephrine reuptake inhibitors (SNRIs), and other antidepressants, including monoamine
oxidase inhibitors (MAOIs). Antidepressants included in each drug class can be found in S1
Table. We also considered individual antidepressant drugs separately. For the figures, the 10
most prescribed antidepressants overall (each representing at least 0.8% of prescriptions) were
included. Any antidepressant prescribed within the study period was included in the preva-
lence analyses. Those with a record of an antidepressant prescription before their study entry
were excluded for the incidence cohort so that only the first antidepressant prescription was
examined.
Covariates
We analysed 4 groups, defined by sex (female and male) and age (5–11 and 12–17 years).
These age groups are similar to those specified in the NICE guidelines on depression in CYP
[5] but exclude 18-year-olds, who may have been treated as adults. We also studied trends and
variation for deprivation, different regions of England, and ethnic groups. Deprivation was
measured using the Townsend deprivation index, an area-based measure of deprivation that
combines information on 4 indicators (unemployment, non-car ownership, non-home owner-
ship, household overcrowding) from the census [28]. Areas are then divided into quintiles
based on their score. When ethnicity information was missing in QResearch, we supplemented
this with the most recent valid ethnic code available in HES. We examined 5 broad ethnic
groups: White, Mixed, Asian, Black, and Chinese or other ethnic group, plus those with no
recorded ethnicity.
Statistical analysis
We calculated incidence rates for being first prescribed an antidepressant and prevalence rates
for people with a first or subsequent antidepressant prescription per 1,000 person-years for
each year between 1998 and 2017. These were produced for the different sex and age groups
for all antidepressants, the drug classes, and individual drugs as described above.
Incidence rate ratios were calculated using multilevel mixed-effects Poisson regression to
take account of any clustering within GP practices for the different sex and age groups. The
fully adjusted models included year, region, Townsend deprivation quintile, and ethnic group.
In order to take account of varying patterns in antidepressant prescribing over time, linear
trends were assessed for different periods using piecewise linear regression [29] with change
points identified by previous studies: 2002 and 2005 [15,17]. The year 2008 was also identified
as a change point for antidepressant prevalence in people aged 14 years and over, but not inci-
dence [17]. We included this and assessed its statistical significance because our study has a
longer follow-up than the previous analysis. Sensitivity analyses recoding the not known ethnic
group to White and examining prescribing by deprivation after excluding London data were
also performed after examining the initial results.
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As a post hoc analysis, we assessed whether the incidence rate ratios (IRRs) for 12- to
17-year-olds from the Poisson regression were linked to other factors in each region. For this,
we plotted the IRRs alongside previously published data from other sources: local authority
spending on ‘low-level’ mental health services (those that are nonspecialist, preventive, and
early intervention, which fall below specialist referral thresholds) per child in the 2018–2019
financial year in regions in England [30] and prevalence estimates of any depressive disorder
and any anxiety disorder for each region from a national survey in England in 2017 of CYP
aged 5–19 years [6].
All analyses were performed using Stata/SE v15 (StataCorp LLC, TX, USA).
Ethics statement
The project was independently peer reviewed and accepted by the QResearch Scientific board
and approved in accordance with the procedure agreed with the Trent Research Ethics Com-
mittee (reference: 18/EM/0400).
Results
The flow chart detailing the selection of the cohort is shown in Fig 1. There were 4,349,638
CYP included in the prevalence study cohort. Of these, 14,537 (0.3%) had their first antide-
pressant prescription before their study entry date and were excluded from the incidence
Fig 1. Flowchart of selection of study participants.
https://doi.org/10.1371/journal.pmed.1003215.g001
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cohort. This left 49,434 CYP who were first prescribed an antidepressant during the study
period. Details of characteristics of the incidence cohort and the subcohort prescribed their
first antidepressant are shown in Table 1. Almost three-quarters of the incidence cohort
(nearly 3.2 million participants) entered the study aged between 5 to 11 years, and the median
follow-up time was 3.6 years (interquartile range: 1.5–7.2 years). Ethnicity information was
available in QResearch for 2,317,010 (53.5%) of the incidence cohort and was supplemented
by HES records for a further 307,810 (7.1%).
Overall, SSRIs (62.6%) were the most commonly prescribed first antidepressant, followed
by TCAs (35.7%) (Table 2). SNRIs (0.5%) and other antidepressants (1.3%) were rarely pre-
scribed as the first antidepressant. The 5 most commonly prescribed first antidepressants were
all either licensed for use in CYP (fluoxetine, imipramine, and sertraline) or mentioned in
NICE guidelines (amitriptyline and citalopram, although citalopram is only recommended as
Table 1. Characteristics of incidence cohort (incidence cohort excludes 14,537 patients with first antidepressant
prescription before study entry) and the subset with a new prescription of any antidepressant during the study
period, age 5 to 17 years, England 1998–2017.
Incidence Cohort Any New
Antidepressant
Prescribed Subcohort
n % n %
Total 4,335,101 100% 49,434 100%
Age� 5–11 years 11.4 m person-years 5,133 10.4%
12–17 years 9.0 m person-years 44,301 89.6%
Sex Female 2,080,843 48.0% 32,571 65.9%
Male 2,254,258 52.0% 16,863 34.1%
Townsend deprivation quintile 1 (least deprived) 973,529 22.5% 11,943 24.2%
2 923,863 21.3% 12,066 24.4%
3 863,260 19.9% 10,856 22.0%
4 800,643 18.5% 8,778 17.8%
5 (most deprived) 761,722 17.6% 5,687 11.5%
Not known 12,079 0.3% 104 0.2%
Region East Midlands 206,792 4.8% 2,816 5.7%
East of England 252,108 5.8% 3,807 7.7%
London 1,056,707 24.4% 5,723 11.6%
North East 148,885 3.4% 1,943 3.9%
North West 672,537 15.5% 7,973 16.1%
South East 887,291 20.5% 13,261 26.8%
South West 430,169 9.9% 5,866 11.9%
West Midlands 474,983 11.0% 5,464 11.1%
Yorkshire & Humber 205,629 4.7% 2,581 5.2%
Ethnicity Not known 1,710,263 39.5% 15,853 32.1%
Known 2,624,838 60.5% 33,581 67.9%
Ethnic group (% of known) White 1,975,726 75.3% 30,731 91.5%
Mixed 86,678 3.3% 566 1.7%
Asian 302,499 11.5% 1,419 4.2%
Black 185,606 7.1% 562 1.7%
Chinese/Other 74,329 2.8% 303 0.9%
�Number of person-years included given for incidence cohort by age, as some people were included in both age
groups over the study period
https://doi.org/10.1371/journal.pmed.1003215.t001
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a second-line antidepressant in the treatment of depression). Over a third of first prescriptions
were fluoxetine, a quarter were amitriptyline, and there were similar proportions of citalopram
(11.8%) and sertraline (11.4%) prescriptions. Despite being licensed for treating obsessive-
compulsive disorder in CYP, fluvoxamine was rarely prescribed as a first antidepressant in the
study period, making up only 0.1% of new prescriptions.
TCAs accounted for over 80% of first antidepressant prescriptions in 5- to 11-year-olds,
and imipramine and amitriptyline were the most commonly first-prescribed individual drugs
in this age group. In adolescents, two-thirds of the newly prescribed antidepressants were
SSRIs. Over the whole study period, fluoxetine (38.3%) and amitriptyline (23.8%) were the
most commonly first-prescribed individual drugs in 12- to 17-year-olds.
Incidence rates
Incidence rates for antidepressant prescribing showed distinct patterns in the age groups and
were highest in 12- to 17-year-old females (S1 Fig).
Antidepressant prescriptions decreased over the study period in 5- to 11-year-olds. For
TCAs, incidence rates decreased by 92% from a peak of 1.6 per 1,000 person-years in males
and by 86% from 0.9 in females in 1999 to less than 0.14 per 1,000 for both sexes in 2017 (Fig
2). SSRI incidence rates, however, increased from 0.05 per 1,000 person-years in females and
Table 2. Number and percentage of CYP with first prescriptions in each drug class and for individual drugs during the study period, England 1998–2017, by age
and sex.
Total 5–11 Years 12–17 Years
Females Males Females Males
n % n % n % n % n %
Any antidepressant 49,434 100% 1,845 100% 3,288 100% 30,726 100% 13,575 100%
Drug class
SSRI 30,949 62.6% 298 16.2% 594 18.1% 20,895 68.0% 9,162 67.5%
TCA 17,624 35.7% 1,538 83.4% 2,674 81.3% 9,285 30.2% 4,127 30.4%
SNRI 263 0.5% 6 0.3% 11 0.3% 161 0.5% 85 0.6%
Other 640 1.3% <5 <0.3% 9 0.3% 414 1.3% 214 1.6%
Individual drug
Fluoxetine 17,493 35.4% 171 9.3% 335 10.2% 11,940 38.9% 5,047 37.2%
Amitriptyline 12,181 24.6% 709 38.4% 921 28.0% 7,627 24.8% 2,924 21.5%
Citalopram 5,828 11.8% 29 1.6% 43 1.3% 4,244 13.8% 1,512 11.1%
Sertraline 5,612 11.4% 83 4.5% 164 5.0% 3,404 11.1% 1,961 14.4%
Imipramine 3,323 6.7% 718 38.9% 1,564 47.6% 424 1.4% 617 4.5%
Paroxetine 1,535 3.1% 12 0.7% 45 1.4% 985 3.2% 493 3.6%
Dosulepin 734 1.5% 5 0.3% 6 0.2% 490 1.6% 233 1.7%
Escitalopram 472 1.0% <5 <0.3% <5 <0.3% 336 1.1% 133 1.0%
Nortriptyline 420 0.8% 19 1.0% 20 0.6% 290 0.9% 91 0.7%
Mirtazapine 404 0.8% <5 <0.3% 6 0.2% 245 0.8% 151 1.1%
Lofepramine 289 0.6% <5 <0.3% 7 0.2% 216 0.7% 62 0.5%
Venlafaxine 225 0.5% <5 <0.3% 10 0.3% 133 0.4% 78 0.6%
Trazodone 165 0.3% <5 <0.3% 23 0.7% 79 0.3% 60 0.4%
Fluvoxamine 61 0.1% <5 <0.3% <5 <0.3% 23 0.1% 31 0.2%
Duloxetine 38 0.1% <5 <0.3% <5 <0.3% 28 0.1% 7 0.1%
Abbreviations: CYP, children and young people; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic
and related antidepressant.
https://doi.org/10.1371/journal.pmed.1003215.t002
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0.06 in males in 1998 to 0.10 in females and 0.17 in males in 2017. Imipramine was initially the
most commonly prescribed individual drug for 5- to 11-year-olds. These rates decreased and
were similar to amitriptyline from 2003 in females and 2006 in males. Fluoxetine and sertraline
incidence rates increased over the study period so that these 4 drugs had similar incidence
rates in 2017 (0.04–0.07 per 1,000 person-years in females and 0.05–0.10 in males).
For 12- to 17-year-olds, antidepressant incidence rates were 2.2 and 2.7 times higher in
2017 than 2005 in females and males, respectively (S1 Fig). TCA incidence rates declined over
the study period to 2.0 per 1,000 person-years in females and 0.7 in males in 2017 (Fig 3). SSRI
incidence rates increased between 1998 and 2002, decreased until 2005, and then increased
again after this reaching a rate of 3.5 per 1,000 in males and 7.6 per 1,000 in females in 2017.
The SSRI incidence rates per 1,000 person-years in 1998, 2002, and 2005 were 3.7, 7.1, and 2.5
in females and 1.1, 2.1, and 0.8 in males. Fluoxetine, sertraline, amitriptyline, and citalopram
have been the 4 most commonly prescribed first antidepressants in 12- to 17-year-olds since
2003 in females and 2008 in males. This is due to a sharp decrease in paroxetine prescribing
after 2002 and decreasing imipramine prescribing. The largest absolute increases were in
Fig 2. Antidepressant drug class and individual drug incidence rates per 1,000 person-years in 5- to 11-year-olds, England, 1998–2017, by sex. SNRI,
serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant
https://doi.org/10.1371/journal.pmed.1003215.g002
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fluoxetine and sertraline prescriptions in males and females, with sertraline becoming the
second most commonly first-prescribed antidepressant for males in 2015 and for females in
2017.
S2–S4 Figs show the crude antidepressant incidence rates over time for 12- to 17-year-olds
by deprivation, region, and ethnicity. These rates were lower for those in the most deprived
group (S2 Fig) and in London than in other areas (S3 Fig). White males and females had the
highest crude incidence rates and Black and Asian groups the lowest (S4 Fig).
IRRs
Fully adjusted IRRs for antidepressant prescribing are shown in Table 3. In 5- to 11-year-olds,
the incidence decreased throughout the time period, with the largest decrease per year between
2002 and 2005. For 12- to 17-year-olds, there was an increase in incidence rates per year from
1998 until 2002, then a decrease until 2005, a small increase until 2008, and then another
increasing trend per year similar in magnitude to the first period.
Fig 3. Antidepressant drug class and individual drug incidence rates per 1,000 person-years in 12- to 17-year-olds, England 1998–2017, by sex. SNRI,
serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant
https://doi.org/10.1371/journal.pmed.1003215.g003
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Antidepressant incidence rates increased with increasing deprivation in all 4 age–sex sub-
groups after adjustment. The strongest trend was seen in 12- to 17-year-old females (adjusted
IRR = 1.12, 95% confidence interval [CI] 1.11–1.13, p< 0.001, per deprivation quintile
increase). However, unadjusted estimates of antidepressant prescribing by deprivation showed
a statistically significant trend of decreasing prescribing with increasing deprivation, driven by
the most deprived quintile, in all age and sex groups apart from 5- to 11-year-old females (S3
Table). For the older age group, adjusting for region resulted in increased prescribing rates
with increasing deprivation, whereas adjusting for year alone did not affect the unadjusted
trend results, and adjusting for just ethnicity attenuated the association but showed those liv-
ing in more deprived areas were still less likely to be prescribed antidepressants. This statisti-
cally significant pattern with deprivation was also shown for 5- to 11-year-old females after
adjusting for region. This association was only evident after taking GP practice clustering into
account in the fully adjusted models (Table 3) in 5- to 11-year-old males. Within London,
there was a statistically significant unadjusted association with deprivation and prescribing in
12- to 17-year-olds, with those living in more deprived areas having lower prescribing rates.
Table 3. IRRs for any antidepressant by age and sex fully adjusted for all variables shown and accounting for clustering by GP practice, England 1998–2017.
5–11 Years 12–17 Years
Females Males Females Males
IRR 95% CI p IRR 95% CI p IRR 95% CI p IRR 95% CI p
Trends within periods
(per year)
1998–2002 0.92 (0.87–0.97) 0.001 0.87 (0.84–0.90) <0.001 1.10 (1.08–1.12) <0.001 1.08 (1.05–1.10) <0.001
2002–2005 0.78 (0.73–0.84) <0.001 0.78 (0.74–0.82) <0.001 0.76 (0.74–0.77) <0.001 0.77 (0.74–0.79) <0.001
2005–2008 0.92 (0.85–0.98) 0.015 0.91 (0.86–0.96) <0.001 1.03 (1.01–1.05) 0.002 1.01 (0.98–1.04) 0.397
2008–2017 0.97 (0.95–1.00) 0.036 0.95 (0.94–0.97) <0.001 1.09 (1.08–1.09) <0.001 1.08 (1.08–1.09) <0.001
Townsend deprivation
quintile
Q1 (least deprived) 1.00 1.00 1.00 1.00
Q2 1.09 (0.95–1.24) 0.226 0.96 (0.87–1.06) 0.432 1.15 (1.11–1.18) <0.001 1.14 (1.09–1.20) <0.001
Q3 1.09 (0.95–1.26) 0.223 1.11 (1.00–1.23) 0.053 1.30 (1.26–1.35) <0.001 1.23 (1.17–1.30) <0.001
Q4 1.25 (1.08–1.46) 0.004 1.18 (1.05–1.32) 0.005 1.46 (1.40–1.52) <0.001 1.37 (1.29–1.45) <0.001
Q5 (most deprived) 1.33 (1.11–1.59) 0.002 1.13 (0.98–1.30) 0.089 1.48 (1.41–1.55) <0.001 1.29 (1.20–1.39) <0.001
Not known 1.51 (0.67–3.39) 0.315 1.27 (0.66–2.45) 0.480 1.12 (0.88–1.44) 0.349 1.18 (0.79–1.76) 0.428
Deprivation trend
(excluding not known)
1.07 (1.03–1.12) 0.001 1.05 (1.02–1.08) 0.002 1.12 (1.11–1.13) <0.001 1.08 (1.07–1.10) <0.001
Region East Midlands 1.00 1.00 1.00 1.00
East of England 0.71 (0.49–1.04) 0.077 0.77 (0.56–1.07) 0.116 1.18 (1.02–1.36) 0.027 1.12 (0.95–1.32) 0.191
London 0.50 (0.37–0.69) <0.001 0.48 (0.37–0.63) <0.001 0.44 (0.39–0.49) <0.001 0.52 (0.45–0.60) <0.001
North East 0.93 (0.61–1.40) 0.716 0.86 (0.60–1.24) 0.422 0.76 (0.64–0.89) 0.001 0.75 (0.62–0.91) 0.004
North West 0.74 (0.54–1.01) 0.062 0.66 (0.50–0.87) 0.003 0.81 (0.72–0.91) 0.001 0.90 (0.78–1.04) 0.153
South East 1.03 (0.76–1.39) 0.861 1.08 (0.83–1.40) 0.570 1.20 (1.06–1.35) 0.003 1.29 (1.12–1.48) <0.001
South West 0.87 (0.63–1.22) 0.422 0.83 (0.62–1.11) 0.205 1.10 (0.96–1.25) 0.162 1.02 (0.87–1.19) 0.827
West Midlands 0.80 (0.57–1.11) 0.174 0.82 (0.62–1.09) 0.173 0.86 (0.76–0.98) 0.024 0.94 (0.81–1.09) 0.433
Yorkshire & Humber 0.99 (0.68–1.45) 0.971 0.98 (0.71–1.36) 0.913 0.81 (0.69–0.94) 0.006 0.77 (0.65–0.93) 0.006
Ethnic group White 1.00 1.00 1.00 1.00
Mixed 0.75 (0.50–1.15) 0.187 0.85 (0.62–1.17) 0.319 0.66 (0.59–0.74) <0.001 0.81 (0.70–0.94) 0.007
Asian 0.70 (0.54–0.89) 0.004 0.64 (0.52–0.78) <0.001 0.41 (0.38–0.44) <0.001 0.47 (0.42–0.52) <0.001
Black 0.71 (0.51–0.98) 0.038 0.56 (0.42–0.75) <0.001 0.32 (0.29–0.36) <0.001 0.32 (0.27–0.38) <0.001
Chinese/Other 0.49 (0.26–0.91) 0.025 0.47 (0.28–0.79) 0.004 0.44 (0.38–0.51) <0.001 0.57 (0.47–0.69) <0.001
Not known 0.52 (0.47–0.58) <0.001 0.54 (0.49–0.58) <0.001 0.45 (0.44–0.46) <0.001 0.41 (0.39–0.42) <0.001
Abbreviations: CI, confidence interval; GP, general practitioner; IRR, incidence rate ratio.
https://doi.org/10.1371/journal.pmed.1003215.t003
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After excluding London in the unadjusted analyses, increased prescribing with increasing dep-
rivation was found for all groups apart from 5- to 11-year-old males, highlighting the influence
of region on these results.
London had the lowest IRRs and the South East had the highest IRRs in all sex and age sub-
groups. The South East estimates were all more than double that of London. The North East
had the second lowest prescribing rate estimates for 12- to 17-year-olds. These estimates were
1.4 (in males) and 1.7 (in females) times higher than the London estimates.
Asian, Black, and Chinese or other ethnic groups, as well as those whose ethnicity was not
known, had statistically significantly lower prescription incidence rates compared with the
White baseline group in 5- to 11-year-olds. For the older age group, the Mixed ethnic group
also had significantly lower incidence rates than the White group. In both males and females,
the lowest IRRs in adolescents were found in the Black group (IRR 0.32, 95% CI 0.27–0.38,
p< 0.001 and IRR 0.32, 95% CI 0.29–0.36, p< 0.001, respectively) compared with the White
group. Results were attenuated in the sensitivity analysis in which the not known ethnic group
were recoded as White (S2 Table). There were no statistically significant differences between
all other ethnic groups and the White/not known baseline for females aged 5–11 years. In
males aged 5–11 years in the Chinese or other (IRR 0.59, 95% CI 0.36–0.99, p = 0.046), Black
(IRR 0.72, 95% CI 0.53–0.96, p = 0.027), and Asian (IRR 0.83, 95% CI 0.68–1.01, p = 0.067)
ethnic groups, the IRRs were still lower than the White/not known group, although the Asian
group was only borderline statistical significance. In the older age group, the attenuated results
showed the same patterns, with only the male Mixed ethnic group no longer statistically signif-
icantly different from the baseline.
Prevalence rates
The prevalence rate patterns overall, in antidepressant drug classes, and in individual drugs
were similar to the incidence rates (S1, S5 and S6 Figs). Prevalence estimates for any antide-
pressant prescriptions were highest for 5- to 11-year-olds in 1999 and decreased over the
study period. Despite a peak in the early 2000s in prescriptions for 12- to 17-year-olds, the
highest rates for males and females were in 2017 (7.9 and 16.4 per 1,000 person-years, respec-
tively). In 12- to 17-year-olds, there were an extra 6.6 females and 3.7 males per 1,000 person-
years who had a second or later antidepressant prescription in 2017. There were very small dif-
ferences between the incidence and prevalence rates in 5- to 11-year-olds throughout the
study period.
S7 Fig shows a negative association between spending per child on ‘low-level’ mental
health services and the prescribing patterns from our study. There appears to be no strong cor-
relation between either spending or prescribing and the depression and anxiety prevalence
estimates.
Discussion
Summary of main results
This study has shown a diverging pattern of decreasing prescribing of antidepressants in 5- to
11-year-olds between 1998 and 2017, whilst rates have more than doubled in 12- to 17-year-olds
since 2005. The most commonly first-prescribed antidepressants are either licensed for use in CYP
or included in national guidelines. Rates of antidepressant prescribing were higher for CYP living in
more deprived areas after accounting for GP practice clustering and region. Children and adoles-
cents living in South East England were more likely to be prescribed antidepressants, and those living
in London the least likely. Prescribing rates were highest in White and lowest in Black adolescents.
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Comparison with other studies
This study has shown that the increase in antidepressant prescribing in CYP in England from
2005 previously found [15–19] has continued until 2017. The 2017 antidepressant prescribing
prevalence rates in adolescents from our study (0.79% and 1.64%) are around half the associ-
ated depressive disorder estimates (1.6% and 3.8%) [6] in males and females, respectively. Cita-
lopram prescribing has previously been found to be higher than in our study—higher than
fluoxetine in 6- to 18-year-olds [16], similar to fluoxetine in under-18s in 2009 [15], and the
second most commonly prescribed antidepressant after fluoxetine in people aged under 20
[20]. Whilst the inclusion of those aged 18 years [16] and over [20] who may have been treated
as adults may explain the higher rates, other methodological differences, such as variation in
factors not accounted for in the unadjusted analyses, could also be important.
A previous study reported that for people of all ages in England, the prevalence of antidepres-
sant prescriptions was lowest in London and highest in the North East of England [24]. We also
found the lowest incident prescription rates in London; however, the North East was the next low-
est area for adolescents. There could be differences in antidepressant prescribing patterns between
CYP and adults, including initiating prescribing and the number of prescriptions because of the
length of time people stay on antidepressants affecting the prevalence analysis, that account for
this difference. Our study examined prescriptions, whilst Grigoroglou and colleagues [24] used
dispensing data, so differences in whether patients filled their prescriptions may also exist.
A report by the Children’s Commissioner into early access to mental health support found
variation in the stated spending on ‘low-level’ preventive and early-intervention (including
nonspecialist psychological support services) services between different regions [30]. London
had the highest spending, and the East of England spent the least per child. We found that the
lowest prescribing for adolescents was in London, which is located between the South East and
East of England regions. These 2 areas had the highest prescribing IRR estimates for 12- to
17-year-olds. S7 Fig shows there appears to be a negative association between spending per
child on ‘low-level’ mental health services (London highest; East of England and South East
lowest) and the prescribing patterns from our study (London lowest; East of England and
South East highest). This implies that antidepressants might be prescribed more frequently to
CYP in areas where there is less investment in preventive services or psychological support
available, although further research is needed to test this hypothesis. That there was no strong
correlation between either spending or prescribing and the depression and anxiety prevalence
estimates could be due to differences in age groups and years studied.
Our study has good face validity because we found similar trends to those published else-
where. For example, we found that after adjustment for GP practice clustering and region,
CYP living in more deprived areas are more likely to receive antidepressant prescriptions com-
pared with those in the less deprived areas, which has previously been shown for children and
adolescents [15,16] and adults [24] in the UK. Although the unadjusted results showed lower
antidepressant prescribing in adolescents living in the most deprived quintile (S2 Fig), this was
due to the lower prescribing and large proportion of people living in the most deprived quin-
tile in London. Excluding London from an unadjusted analysis of trend over deprivation
changed the estimates in 12- to 17-year-olds from 0.96 (p< 0.001) in both sexes to 1.06 in
females and 1.05 in males (both p< 0.001) (S3 Table). Measures of deprivation were not
found to be statistically significantly associated with spending on CYP mental health per child
at the Clinical Commissioning Group level in a study by Rocks and colleagues [31]. This study
included early help and targeted services (tier 2) and specialised Child and Adolescent Mental
Health Services (CAMHS) (tier 3). Spending on early interventions by nonspecialists (tier 1)
could influence antidepressant prescriptions and might be linked to deprivation.
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Strengths and limitations
The main strengths of this study are its size, representativeness, and duration. We analysed
data from over 4.3 million CYP across England over a 20-year period, which, to our knowl-
edge, is the largest study to date on antidepressant prescribing in CYP. The vast majority of the
UK population are registered with a GP practice [13], and the QResearch database is the most
nationally representative primary care database in England [32] with comprehensive informa-
tion on prescriptions. This means that the results are likely to generalise well within the UK.
We have been able to examine a long time series for different sex and age groups and investi-
gate variation by deprivation, region, and ethnicity whilst taking all these factors into account.
A limitation of the study is that it does not include any secondary care prescriptions. There is
no publicly available information about antidepressant prescribing for CYP in secondary care in
the UK. Most parents would initially first visit a GP with concerns about their child’s mental health
issues [33]. The GP would refer them to a specialist in child and mental health following if appro-
priate [5,10]. Furthermore, in the UK, GPs are typically responsible for the ongoing prescribing of
antidepressant medicines if initiated by a specialist. It is possible that what we have identified as a
first prescription is actually a subsequent prescription in primary care following an initial prescrip-
tion in secondary care. Without secondary care prescriptions, the prevalence estimates will be
underestimates of the total antidepressant prescriptions in CYP. However, the prevalence patterns
should be unaffected by who initiated the first prescription if prescribing is transferred to primary
care. We were only able to assess whether antidepressants were prescribed, not whether they were
dispensed or taken. Unmeasured confounding may also still be present. We chose to include all
CYP regardless of whether they had an appropriate indication recorded and cannot be sure that
particular antidepressants were prescribed for the indications they are licensed for.
Because we used data routinely recorded in primary care rather than prospectively collecting
the data specifically for the study, not all information we required was available. Despite using
all available ethnicity information from QResearch and HES records, ethnicity was still missing
for 40%. As a sensitivity analysis, we recoded those with no ethnicity information to a new
White/not known group. This attenuated the results for the other ethnic groups, but these were
still statistically significant for females aged 12–17 years, males aged 12–17 years (apart from the
Mixed group), and Black and Chinese or other ethnic groups in males aged 5–11 years.
Implications
Our study was not designed to determine whether increased prescribing of antidepressants in
CYP since 2005 is due to increasing rates of mental health problems, greater awareness and
help-seeking for those with mental health issues, prescribing behaviour, patient choice, or
because there are issues with accessing other psychological therapies [6]. Generally, the antide-
pressants prescribed to CYP appear to be those licensed for use in under-18s in the UK or
listed for use with particular indications in the British National Formulary for Children [8]
despite not being licensed. The rapid recent increase of sertraline as the first antidepressant
prescribed is of interest. Sertraline is licensed in the UK for use in CYP for obsessive-compul-
sive disorder and recommended as a second-line treatment for major depression in CYP by
NICE [5]. The prevalence of obsessive-compulsive disorder is low in England (0.4% in 2017)
[6], and as a second-line drug, sertraline would not be expected to be the first antidepressant
prescribed for major depression. There are currently no UK guidelines on treating CYP with
anxiety, although meta-analyses have shown SSRIs, including sertraline, to be effective [34].
General practitioners may be following the adult guidance, which suggests sertraline and was
published in 2011 [35], after which female adolescent sertraline prescription rates rapidly
increased. The relatively high prescribing rates of amitriptyline should be explored further to
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determine what indications this drug is being prescribed for. Whilst amitriptyline is unlicensed
for use in CYP, it is included in NICE guidelines for treating headaches [12] and the British
National Formulary for Children for treating neuropathic pain [8]. TCAs in general are not
recommended for depressive disorder in CYP and those who self-harm [36] because of life-
threatening cardiac risks associated with overdose, but rates of self-harm have been shown to
be increasing in 13- to 16-year-olds in recent years in the UK [37]. Understanding which indi-
cations are recorded around the time of these first antidepressant prescriptions is important,
and work examining this has been analysed separately [14].
Future work should further examine whether any barriers in awareness, access to appropri-
ate healthcare services, and treatment exist, and if so, whether they vary for different groups and
how they can be tackled. Determining whether increased spending on preventive, early-inter-
vention services and access to psychological therapies leads to lower antidepressant prescription
rates, and how these services compare in terms of outcomes is an important area of work that
could lead to possible savings in healthcare spending and improved health for the population.
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21. Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, et al. Outpatient antidepressant
drug use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidem Dr S.
2017; 26(2):170–9. https://doi.org/10.1002/pds.4138 PMID: 27868277
PLOS MEDICINE Antidepressant prescribing in children and young people in England
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003215 July 22, 2020 17 / 18
22. Revet A, Montastruc F, Raynaud JP, Baricault B, Montastruc JL, Lapeyre-Mestre M. Trends and Pat-
terns of Antidepressant Use in French Children and Adolescents From 2009 to 2016: A Population-
Based Study in the French Health Insurance Database. J Clin Psychopharm. 2018; 38(4):327–35.
https://doi.org/10.1097/JCP.0000000000000891 PMID: 29851707
23. Lagerberg T, Molero Y, D’Onofrio BM, Fernandez de la Cruz L, Lichtenstein P, Mataix-Cols D, et al.
Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children,
adolescents, and young adults: a population-based study in Sweden. Eur Child Adoles Psy. 2019; 28
(8):1137–45. https://doi.org/10.1007/s00787-018-01269-2 PMID: 30659386
24. Grigoroglou C, Munford L, Webb RT, Kapur N, Ashcroft DM, Kontopantelis E. Prevalence of mental ill-
ness in primary care and its association with deprivation and social fragmentation at the small-area
level in England. Psychol Med. 2020; 50(2):293–302. https://doi.org/10.1017/S0033291719000023
PMID: 30744718
25. Walters P, Ashworth M, Tylee A. Ethnic density, physical illness, social deprivation and antidepressant
prescribing in primary care: ecological study. Br J Psychiatry. 2008; 193(3):235–9. https://doi.org/10.
1192/bjp.bp.107.038299 PMID: 18757984
26. Schofield P, Das-Munshi J, Mathur R, Congdon P, Hull S. Does depression diagnosis and antidepres-
sant prescribing vary by location? Analysis of ethnic density associations using a large primary-care
dataset. Psychol Med. 2016; 46(6):1321–9. https://doi.org/10.1017/S0033291715002913 PMID:
26879871
27. Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Cipriani A, et al. Trends in antidepressant pre-
scriptions in children and young people in England, 1998–2017: protocol of a cohort study using linked
primary care and secondary care datasets. Evid Based Ment Health. 2019; 22(3):129–33. https://doi.
org/10.1136/ebmental-2019-300097 PMID: 31253602
28. Townsend P. Deprivation. J Soc Policy. 1987; 16:125–46. https://doi.org/10.1017/
S0047279400020341 WOS:A1987J267500001
29. Gould WW. Linear splines and piecewise linear functions. Stata Technical B. 1993; 15:13–7.
30. Children’s Commissioner. Early access to mental health support. London: Children’s Commissioner
for England; 2019.
31. Rocks S, Fazel M, Tsiachristas A. Variation in spend on young mental health across Clinical Commis-
sioning Groups in England: a cross-sectional observational study. BMJ Open. 2019; 9(10):e030011.
https://doi.org/10.1136/bmjopen-2019-030011 PMID: 31594880
32. Kontopantelis E, Stevens RJ, Helms PJ, Edwards D, Doran T, Ashcroft DM. Spatial distribution of clini-
cal computer systems in primary care in England in 2016 and implications for primary care electronic
medical record databases: a cross-sectional population study. BMJ Open. 2018; 8(2):e020738. https://
doi.org/10.1136/bmjopen-2017-020738 PMID: 29490968
33. Rainer C, Crellin R. Finding Help: Children, young people and families navigating the system to get the
mental health support they need. London, UK: The Children’s Society; 2019.
34. Wang Z, Whiteside SPH, Sim L, Farah W, Morrow AS, Alsawas M, et al. Comparative Effectiveness
and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A
Systematic Review and Meta-analysis. JAMA Pediatr. 2017; 171(11):1049–56. https://doi.org/10.1001/
jamapediatrics.2017.3036 PMID: 28859190
35. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in
adults: management (Clinical guideline CG113). 2011 [cited 2020 May 11]. Available from: https://www.
nice.org.uk/guidance/cg113 PMID: 22536620
36. National Institute for Health and Care Excellence. Self-harm in over 8s: long-term management (Clinical
guideline CG133). 2011 [cited 2020 May 11]. Available from: https://www.nice.org.uk/guidance/cg133
37. Morgan C, Webb RT, Carr MJ, Kontopantelis E, Green J, Chew-Graham CA, et al. Incidence, clinical
management, and mortality risk following self harm among children and adolescents: cohort study in pri-
mary care. BMJ. 2017; 359. https://doi.org/10.1136/bmj.j4351 PMID: 29046278
PLOS MEDICINE Antidepressant prescribing in children and young people in England
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003215 July 22, 2020 18 / 18
